BioInvent International AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 71.46 million compared to SEK 326.13 million a year ago. Net loss was SEK 330.3 million compared to SEK 42.5 million a year ago.

Basic loss per share from continuing operations was SEK 5.02 compared to SEK 0.69 a year ago. Diluted loss per share from continuing operations was SEK 5.02 compared to SEK 0.69 a year ago.